Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Barry I. Eisenstein"'
Autor:
Roger Echols, John H. Rex, George H. Talbot, Aaron Dane, John F. Tomayko, Michael N. Dudley, Mark Goldberger, Barry I. Eisenstein
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Summary From a public health perspective, new antibacterial agents should be developed before widespread resistance to existing agents emerges. Anticipatory drug development based on noninferiority trials offers a path to making safe and efficacious
Autor:
Barry I. Eisenstein, Aaron Dane, Cindy Lancaster, Robert F. Meyer, Ian Friedland, Jeff Alder, John F. Tomayko, Jennifer Jackson, Wendy R Sanhai, John H. Rex, Charles Knirsch, Mark Goldberger
Publikováno v:
The Lancet Infectious Diseases. 13:269-275
To bring new antibacterial drugs to the market is challenging because discovery of new agents is difficult, two large trials per indication are needed in accordance with traditional regulatory requirements, and the economic reward is limited if the u
Autor:
Helen W. Boucher, Martin J. Blaser, Dale N. Gerding, John S. Bradley, Ruth Lynfield, Schwartz D, David N. Gilbert, Robert Guidos, Barry I. Eisenstein, Edward Septimus, John H. Rex, Brad Spellberg, L B Reller, Fred C. Tenover
Publikováno v:
Clinical Infectious Diseases. 52:S397-S428
Publikováno v:
Clinical Pharmacology & Therapeutics. 96:166-168
The antibiotic pipeline is thin and lacks diversity, particularly for agents targeting Gram-negative pathogens. The reasons for our anemic global development pipeline are often summarized as (i) discovery of new antibiotics is difficult, (ii) clinica
Publikováno v:
Clinical Infectious Diseases. 50:S10-S15
Daptomycin has been approved and successfully launched for the treatment of complicated skin and skin-structure infections caused by gram-positive pathogens [1] and bacteremia and right-sided endocarditis due to Staphylococcus aureus, including strai
Autor:
G. Ralph Corey, Barry I. Eisenstein, Donald P. Levine, Susan J. Rehm, Helen W. Boucher, Gloria Vigliani, Elias Abrutyn, Marilyn Campion
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to methicillin-resistant S. aureus (MRSA) infection are in
Autor:
Barry I. Eisenstein
Publikováno v:
Expert Opinion on Drug Discovery. 2:1523-1536
Gram-positive bacteria such as Staphylococcus aureus are important human pathogens. An increasing proportion of S. aureus are methicillin resistant. For decades, methicillin-resistant S. aureus infections have been treated with vancomycin, but suscep
Publikováno v:
Infectious Diseases in Clinical Practice. 12:322-327
Background:Complicated urinary tract infections (UTIs) due to Gram-positive pathogens are of increasing concern because of steadily emerging resistance to standard antibiotic therapy. Daptomycin is the first available agent of a new class of antibiot
Autor:
Barry I. Eisenstein
Publikováno v:
Expert Opinion on Investigational Drugs. 13:1159-1169
The increasing incidence of serious infections caused by antibiotic-resistant Gram-positive bacteria has led to the development of new spectrum-specific agents. One such agent is Cubicin (daptomycin for injection), the first member of a new class of
Publikováno v:
Annals of the New York Academy of Sciences
The rising tide of antibacterial resistance and the lack of a diverse, vibrant pipeline of novel antibacterial agents is a global crisis that impairs our ability to treat life-threatening infections. The recent introduction of a tiered approach to th